Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease A Randomized Controlled Trial Comparing Dapagliflozin Plus Mesalamine Versus Mesalamine Alone

What this Trial Is About

Researchers are studying inflammatory bowel diseases (IBD), which include Crohn's disease and ulcerative colitis (UC). These complex, recurring conditions cause symptoms like severe diarrhea, abdominal pain, weight loss, and fatigue, sometimes leading to serious complications. The study aims to evaluate the effects of dapagliflozin combined with mesalamine on IBD by focusing on how activating autophagy and suppressing cell death may reduce disease activity. Participants will be randomly assigned to one of two groups for six months. One group will receive mesalamine alone, taken as 1 gram three times daily. The other group will take the same mesalamine dose plus dapagliflozin 10 mg once daily. Both treatments are drugs being studied to assess their impact on IBD symptoms and inflammation. During the study, researchers will monitor participants over six months, measuring changes in the Mayo score, a tool used to assess UC severity. Participants will have regular evaluations to track symptoms and disease progression. The study is double-blinded, meaning neither the participants nor the researchers know who is receiving which treatment, to ensure unbiased results. This trial is designed for adults aged 18 to 60 with mild to moderate ulcerative colitis.

Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease